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Introduction {#sec1}
============

Incidence of obesity and nonalcoholic fatty liver disease (NAFLD) has been increasing rapidly and is now the most common cause of chronic liver diseases worldwide ([@bib33], [@bib34]). NAFLD may develop into nonalcoholic steatohepatitis and increase the risk of cardiovascular diseases and mortality; however, efficient treatment to block or slow down progression of NAFLD is still lacking ([@bib15], [@bib34]). Genome-wide association studies (GWAS) have been instrumental to pinpoint important susceptible genes and possible therapeutic targets ([@bib1]) in complex traits. Genetic variants in the FAM13A (Family with Sequence Similarity 13, Member A) locus has been reported to be associated with HDL cholesterol and body mass index (BMI)-adjusted fasting insulin levels ([@bib17], [@bib29]), two relevant phenotypes for liver diseases. Furthermore, FAM13A locus has also been identified for its significant association with waist-to-hip ratio (WHR) adjusted for body mass index (WHRadjBMI) ([@bib24]) and visceral to subcutaneous fat ratio ([@bib11]).

Recently, FAM13A was reported to interact and stabilize IRS1 from degradation, thereby enhancing insulin signaling in adipocytes ([@bib28]). In contrast, another group reported that Fam13a is dispensable for adipose development and insulin sensitivity in adipose tissue ([@bib27]), suggesting complex regulation of glucose metabolism by FAM13A in adipose tissue. However, whether FAM13A regulates hepatic insulin sensitivity and lipid metabolism and their roles in fatty liver development are not explored yet.

In this study, we find that rs2276936 in the FAM13A locus, associated with multiple metabolic traits including HDL levels, demonstrated allelic enhancer activity. Furthermore, we find that *Fam13a*^*−/−*^ mice showed improved hepatic insulin sensitivity and increased hepatic AMP-activated protein kinase (AMPK) activity, a major regulator in maintaining energy homeostasis and preventing against hepatic steatosis ([@bib5], [@bib30]). These changes may collectively contribute to ameliorated high-fat diet (HFD)-induced obesity and nonalcoholic fatty liver in *Fam13a*^*−/−*^ mice.

Results {#sec2}
=======

RS2276936 within FAM13A Gene Associated with HDL and Fat Mass Exerts Allelic Activity {#sec2.1}
-------------------------------------------------------------------------------------

Previously, we performed massively parallel reporter assays (MPRA) to assess allele-specific enhancer activity of SNPs within FAM13A GWAS locus ([@bib2]) and identified 45 SNPs with significant allelic effects. Given that the FAM13A locus associated with multiple metabolic traits including HDL levels, we further queried the association of these 45 MPRA SNPs with HDL levels using GWAS data from Global Lipids Genetics Consortium ([@bib29]) (<http://csg.sph.umich.edu/abecasis/public/lipids2013/>). We found that three tightly correlated MPRA SNPs (r^2^\> 0.9) demonstrated genome-wide (rs2276936, p \< 10^−8^) or sub-genome-wide significance (rs2167750 and rs7695177, p \< 10^−5^) of association with HDL levels ([Table S1](#mmc1){ref-type="supplementary-material"}). Furthermore, these three SNPs are tightly correlated with previously published top GWAS SNPs associated with lipid traits including rs3822072 ([@bib31]) and rs9991328 ([@bib31]) (r^2^\> 0.9 for all pairwise comparison). Major and minor haplotypes of these five SNPs comprised of \>90% population of all ethnic groups ([@bib18], [@bib19]) ([Figure 1](#fig1){ref-type="fig"}A). We also evaluated the association of these three SNPs, rs2276936, rs2167750, and rs7695177 with over 2000 complex traits from UK Biobank ([@bib7]). They were associated with body fat distribution at genome-wide significance (p \< 5 × 10^−8^) ([Table S2](#mmc1){ref-type="supplementary-material"}).Figure 1Identification of Functional Variants at the FAM13A Locus Associated with Lipid Levels(A)LD matrix of SNPs (rs2276936, rs2167750, rs7695177) with previously frequently reported top GWAS SNPs (rs3822072 and rs9991328). The first two columns represent the major (red frame) and minor (blue frame) haplotypes of these five SNPs.(B--D) (B) Top: the diagram shows the ATAC-Seq and DNase-Seq signals around SNP rs2276936, rs2167750, and rs7695177 in liver-relevant cell and tissues profiled by Roadmap epigenomics project and ENCODE project. Bottom: reporter assays of FAM13A promoter with or without DNA regions spanning rs2276936, rs2167750, and rs7695177 in HepG2 cells. For: forward orientation; Rev: reverse orientations. Data are presented as mean ± SEM from three biological replicates with triplicate wells in each repeat. ∗p \< 0.05 by unpaired Student\'s t test. Expression of FAM13A was assessed in HepG2 cells transfected with gRNA targeting rs2276936 for regional deletion (C) or indel deletion (D). Con: Control. Rs227-1 and rs227-2 are from two independent repeats. Data are presented as mean ± SEM from two biological replicates with triplicate wells in each repeat. ∗p \< 0.05 by unpaired Student\'s t test.

Furthermore, we analyzed open chromatin status nearby three SNPs, rs2276936, rs2167750, and rs7695177 in primary human hepatic tissues and hepatocytes available from Roadmap epigenomics and ENCODE (encyclopedia of DNA elements) projects ([@bib10], [@bib14]). The DNA region nearby rs2276936 showed highest open chromatin scores among three SNPs, suggesting active regulatory element nearby this SNP in human liver tissues or cells ([Figure 1](#fig1){ref-type="fig"}B). To further investigate the regulatory effects of these three SNPs on the expression of FAM13A, we performed reporter assays by cloning the endogenous promoter of FAM13A gene and preceding SNP regions with one of two opposing alleles for each SNP into the luciferase constructs. The primers used for molecular cloning of reporter constructs are shown in [Table S3](#mmc1){ref-type="supplementary-material"}. After transfection into HepG2 cells, rs2276936 demonstrated significant allelic effects ([Figure 1](#fig1){ref-type="fig"}B), with A-allele at forward orientation associated with higher luciferase activity. Furthermore, we engineered the CRISPR/Cas-9 constructs with either gRNA pairs to generate a ∼100bp deletion ([Figure 1](#fig1){ref-type="fig"}C) or a single gRNA to generate an indel ([Figure 1](#fig1){ref-type="fig"}D) spanning rs2276936. Sequence of gRNAs used for deletion generation nearby the rs2276936 is shown in [Table S4](#mmc1){ref-type="supplementary-material"}. After transfection of these CRISPR constructs into HepG2 cells, we found that deletion of rs2276936 region led to 30% reduction in the expression of FAM13A, suggesting an enhancer activity of the DNA region spanning rs2276936.

Collectively, these data strongly suggested rs2276936 associated with HDL-regulated expression of FAM13A in an allele-specific manner with rs2276936C allele associated with lower enhancer activity in HepG2 cells.

Fam13a Deficiency Ameliorates HFD-induced Body Weight Gain {#sec2.2}
----------------------------------------------------------

Given that FAM13A was associated with multiple metabolic phenotypes in GWAS, we investigated metabolic phenotypes of Fam13a knockout mice that we have previously generated ([@bib12]). Consistent with the previous report, *Fam13a*^*−/−*^ mice demonstrated similar body weights, serum-free fatty acid levels, and triglycerides levels as compared with wild-type littermate control mice (*Fam13a*^*+/+*^) ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D) when fed on normal chow diet. However, total cholesterol levels are reduced in *Fam13a*^*−/−*^ mice compared with *Fam13a*^*+/+*^ ([Figure S1](#mmc1){ref-type="supplementary-material"}E), suggesting that Fam13a is required to maintain normal cholesterol levels.

HFD-treated mice chronically develop multiple metabolic changes, seen in fatty liver disease, an increasing global health burden ([@bib21]). To determine roles of FAM13A in this process, we treated mice with HFD for four months. In contrast to *Fam13a*^*+/+*^ mice, *Fam13a*^*−/−*^ mice demonstrated less body weight gain starting at two months of HFD treatment ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A) and increased lean mass and reduced fat mass after four months of HFD feeding ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B), likely attributable to decreased mass of inguinal fat ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C) rather than brown or epididymal fat ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2H). Furthermore, liver mass is also reduced in HFD-treated *Fam13a*^*−/−*^ mice ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D). However, oxygen consumption (VO2) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), energy expenditure (EE) ([Figure S3](#mmc1){ref-type="supplementary-material"}C), respiratory exchange rate ([Figure S3](#mmc1){ref-type="supplementary-material"}D), and food intake ([Figure S3](#mmc1){ref-type="supplementary-material"}E) were comparable in *Fam13a*^*−/−*^ mice and *Fam13a*^*+/+*^ mice after seven weeks of HFD treatment.Figure 2Body Weight Gain in Mice after High-Fat diet (HFD) Treatment for Four Months(A) Gain of body weight measured during HFD treatment for four months in *Fam13a*^*+/+*^ (n = 7) and *Fam13a*^*−/−*^ mice (n = 5).(B--D) (B) Fat and lean mass of mice (A) measured by MRI after four months of HFD treatment. Inguinal fat (C) and liver (D) mass normalized to body weight in mice treated with HFD (n = 6 for *Fam13a*^*+/+*^; n = 5 for *Fam13a*^*−/−*^). Data are presented as mean ± SEM. ∗p \< 0.05 or ∗∗p \< 0.01 by unpaired Student\'s t test.

*Fam13a*^*−/−*^ Mice Display Improved Hepatic Insulin Sensitivity and Reduced Hepatic Glucose Production {#sec2.3}
--------------------------------------------------------------------------------------------------------

To assess glucose homeostasis, we performed glucose tolerance test (GTT) and insulin tolerance test (ITT) on *Fam13a*^*−/−*^ mice and wild-type littermates after 14 weeks of HFD treatment. Despite similar fasting glucose levels ([Figure S2](#mmc1){ref-type="supplementary-material"}I) and glucose tolerance ([Figure 3](#fig3){ref-type="fig"}A), *Fam13a*^*−/−*^ mice demonstrated increased insulin sensitivity as suggested by ITT assay ([Figure 3](#fig3){ref-type="fig"}B), indicating that *Fam13a* deficiency sensitizes mice to insulin response. However, we detected reduced insulin levels in serum from *Fam13a*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}C), indicating a plausible feedback due to increased insulin sensitivity.Figure 3*Fam13a*^*−/−*^ Mice Showed Improved Systemic and Hepatic Insulin Sensitivity after HFD Treatment(A and B) (A) Glucose tolerance test (GTT) and (B) insulin tolerance test (ITT) were performed after overnight fasting or 6-h fasting in female *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice fed with HFD for 14 weeks, respectively.(C) Serum insulin was measured in female *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice fed with HFD for four months.(D) Immunoblotting of phosphorylation of Akt (Thr308) in liver from HFD-fed *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice for four months with or without insulin injection via portal vein. Mice were harvested five minutes after insulin treatment. Mean ± SEM shown represent the densitometry of bands averaged from 3 to 4 mice/group. ∗p \< 0.05 or ∗∗p \< 0.01 by unpaired Student\'s t test.(E) Akt phosphorylation at Thr308 was measured in primary hepatocytes cultured in the presence or absence of insulin at the concentration of 100 nM for 6 h. INS, insulin.(F) Hepatic glucose production was measured and normalized to total cellular protein amount in hepatocytes isolated from *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice. (Mean ± SEM from three mice/genotypes). ∗p \< 0.05, unpaired Student\'s t test.

Because liver is critical in systemic glucose homeostasis, we analyzed hepatic insulin signaling pathway via portal vein injection of insulin into HFD-fed *Fam13a*^*−/−*^ mice. Increased phosphorylation of Akt (p-Akt) (Thr308) was observed in *Fam13a*^*−/−*^ mice compared with *Fam13a*^*+/+*^ controls five minutes after insulin stimulation ([Figure 3](#fig3){ref-type="fig"}D). Furthermore, primary *Fam13a*^*−/−*^ hepatocytes also demonstrated increased levels of p-Akt after insulin treatment *ex vivo* compared with *Fam13a*^*+/+*^ cells ([Figure 3](#fig3){ref-type="fig"}E), suggesting increased hepatic insulin sensitivity in *Fam13a*^*−/−*^ hepatocytes. Additionally, hepatic glucose production was also significantly decreased in isolated primary *Fam13a*^*−/−*^ hepatocytes, compared with *Fam13a*^*+/+*^ cells ([Figure 3](#fig3){ref-type="fig"}F), suggesting that deficiency of Fam13a may lead to intrinsic reduction of gluconeogenesis in hepatocytes.

Partially consistent with recent findings that Fam13a may increase IRS-1 levels in white adipose tissues ([@bib28]), we found a trend toward reduced levels of IRS-1 in epididymal fat ([Figure S4](#mmc1){ref-type="supplementary-material"}A) whereas slightly increased IRS-1 levels in both inguinal fat ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and liver tissues ([Figure S4](#mmc1){ref-type="supplementary-material"}C) compared with *Fam13a*^*+/+*^ control mice, suggesting that the regulation of Fam13a on insulin signaling in adipocytes is depot dependent.

FAM13A Regulates Lipid Metabolism and *Fam13a*^*−/−*^ Mice Are Resistant to HFD-Induced Fatty Liver {#sec2.4}
---------------------------------------------------------------------------------------------------

Given that the FAM13A locus is associated with HDL levels in GWAS, we also measured lipid levels in HFD-fed mice. *Fam13a*^*−/−*^ mice showed significantly reduced levels of LDL/VLDL and total cholesterol ([Figure 4](#fig4){ref-type="fig"}A) in serum. Although levels of HDL ([Figure 4](#fig4){ref-type="fig"}A) and triglycerides ([Figure S5](#mmc1){ref-type="supplementary-material"}A) in serum are comparable between *Fam13a*^*−/−*^ and *Fam13a*^*+/+*^ mice, expression of the apolipoprotein A-I (Apoa1) gene that encodes major component of HDL was significantly increased in isolated hepatocytes ([Figure 4](#fig4){ref-type="fig"}B) and showed a trend toward increased levels in liver samples ([Figure S5](#mmc1){ref-type="supplementary-material"}B) from *Fam13a*^*−/−*^ mice compared with *Fam13a*^*+/+*^ littermates.Figure 4HFD-fed *Fam13a*^*−/−*^ Mice Showed Improved Hepatic Steatosis(A) Levels of total cholesterol, HDL, and LDL/VLDL were determined in serum from *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice after HFD treatment for four months.(B--E) (B) Expression of Apoa1 was measured in primary hepatocytes from *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice using q-PCR. Free fatty acid (C), triglycerides (D), and cholesterol (E) were measured in murine liver samples. Data are presented as mean ± SEM. ∗p \< 0.05 or ∗∗p \< 0.01, unpaired Student\'s t test.(F) Representative images of HE staining of livers are shown. (n = 6 for *Fam13a*^*+/+*^; n = 5 for *Fam13a*^*−/−*^ mice). Scale bar: 20 μm.

Chronic HFD treatment results in lipid accumulation in the liver, leading to fatty liver disease ([@bib21]). However, significantly lower levels of free fatty acid ([Figure 4](#fig4){ref-type="fig"}C), triglycerides ([Figure 4](#fig4){ref-type="fig"}D), and total cholesterol ([Figure 4](#fig4){ref-type="fig"}E) were detected in liver samples from *Fam13a*^*−/−*^ mice compared with *Fam13a*^*+/+*^ control mice fed with HFD. We observed much less lipid accumulation in the livers of *Fam13a*^*−/−*^ mice as compared with HFD-fed *Fam13a*^*+/+*^ mice ([Figure 4](#fig4){ref-type="fig"}F). Collectively, these data suggest that Fam13a deficiency ameliorates HFD-induced fatty liver. However, expression of inflammatory cytokines was comparable between these two genotypes ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5I).

Increased Mitochondrial Function and Activation of the AMPK Signaling in Hepatocytes from *Fam13a*^*−/−*^ Mice {#sec2.5}
--------------------------------------------------------------------------------------------------------------

To determine the mechanism for improved fatty liver in *Fam13a*^*−/−*^ mice after HFD treatment, we assessed several possibilities including lipolysis, hepatic lipogenesis, mitochondrial function such as oxidative phosphorylation, and fatty acid oxidation in hepatocytes. First, lipolysis induced by injection of isoproterenol, a β3-adrenergic agonist, stimulated a significant increase of free fatty acid release in both *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice with negligible genotypic difference ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Secondly, expression of lipogenic genes including sterol regulatory element-binding transcription factor (Srebf1), a critical transcription factor to activate lipogenic gene ([@bib8]), and its target, fatty acid synthase (Fasn) ([@bib23]), were comparable in liver samples from *Fam13a*^*−/−*^ and *Fam13*^*+/+*^ mice ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). Lastly, expression of critical genes for fatty acid β-oxidation, medium-chain acyl-coenzyme A dehydrogenase (Acadm), was increased in liver samples from HFD-fed *Fam13a*^*−/−*^ mice ([Figure S6](#mmc1){ref-type="supplementary-material"}D), in contrast to carnitinepalmitoyltransferase 1A (Cpt1a) ([Figure S6](#mmc1){ref-type="supplementary-material"}E).

We then assessed mitochondrial function in primary hepatocytes. Indeed, basal and maximal mitochondrial respiration were significantly increased in *Fam13a*^*−/−*^ hepatocytes, compared with *Fam13a*^*+/+*^ hepatocytes as measured by Seahorse assay ([Figures 5](#fig5){ref-type="fig"}A and 5B), suggesting increased mitochondrial oxidative phosphorylation in primary hepatocytes under Fam13a deficiency. Consistently, expression of peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (Ppargc1α), the master regulator of mitochondrial biogenesis and oxidative phosphorylation ([@bib13]), is increased in *Fam13a*^*−/−*^ hepatocytes, compared with *Fam13a*^*+/+*^ hepatocytes ([Figure S6](#mmc1){ref-type="supplementary-material"}F).Figure 5FAM13A Regulates Mitochondrial Function in Primary Hepatocytes(A) Mitochondrial respiration was measured by Seahorse assay in hepatocytes isolated from *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice. Arrows indicate the sequential addition of oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and rotenone/antimycin treatments. Representative results of one pair of mice from two biological replicates.(B--E) (B) The basal oxygen consumption rate (OCR), maximal mitochondrial respiration, ATP production, and non-mitochondrial respiration from A are shown. Data are presented as mean ± SD. ∗∗p \< 0.01 by unpaired Student\'s t test. Phosphorylation of AMPK (Thr172) was measured in the liver samples from HFD-fed *Fam13a*^*+/+*^ and *Fam13a*^*−/−*^ mice (C, n = 4--5 mice/genotype), in primary hepatocytes (D) and HepG2 cells transfected with small interfering RNA (siRNA) targeting FAM13A (E). Data are presented as mean ± SEM. ∗p \< 0.05, ∗∗p \< 0.01 by unpaired Student\'s t test.

Furthermore, we determined the activity of AMPK, a critical regulator in energy homeostasis, in *Fam13a*^*−/−*^ liver samples. Accompanied by improved fatty liver in *Fam13a*^*−/−*^ mice, AMPK activation as indicated by phosphorylation of AMPK (Thr172) was significantly enhanced in liver from *Fam13a*^*−/−*^ mice fed with HFD ([Figure 5](#fig5){ref-type="fig"}C). Increased activation of AMPK was also detected in primary hepatocytes from *Fam13a*^*−/−*^ mice fed on normal chow, suggesting an intrinsic inhibition on AMPK in hepatocytes by FAM13A ([Figure 5](#fig5){ref-type="fig"}D). This was further confirmed by increased AMPK activation detected in HepG2 cells transfected with FAM13A siRNA ([Figure 5](#fig5){ref-type="fig"}E). These data indicate that deficiency of *Fam13a* led to hepatic activation of AMPK pathway that may contribute to less body weight gain and ameliorated fatty liver in *Fam13a*^*−/−*^ mice under HFD treatment.

FAM13A Regulates Mitochondrial Function through AMPK Signaling {#sec2.6}
--------------------------------------------------------------

Furthermore, overexpression of FAM13A reduced basal and maximal mitochondrial respiration, and ATP production ([Figure 6](#fig6){ref-type="fig"}A), accompanied by decreased phosphorylation level of AMPK (Thr172) ([Figure 6](#fig6){ref-type="fig"}B) in HepG2 cells. To determine whether FAM13A regulates mitochondrial function through AMPK, stable knockdown of AMPK or FAM13A was established in HepG2 cells by shRNA targeting AMPKα and/or FAM13A, as opposed to scramble RNA control. Although knockdown of FAM13A led to increased mitochondrial respiration ([Figures 6](#fig6){ref-type="fig"}C--6E), this was abolished by silencing of AMPK. Taken together, these data suggest that FAM13A regulates mitochondrial function through dephosphorylation and inactivation of AMPK and thus possibly promotes lipid accumulation in hepatic cells ([Figure 7](#fig7){ref-type="fig"}A).Figure 6FAM13A Regulates Mitochondrial Respiration through AMPK Signaling(A) The basal mitochondrial respiration, maximal mitochondrial respiration, ATP production, and non-mitochondrial respiration were shown in HepG2 cells transfected with the plasmid expressing FAM13A or empty vector. Data are presented as mean ± SEM. ∗p \< 0.05, ∗∗p \< 0.01 by unpaired Student\'s t test.(B) Phosphorylation of AMPK (Thr172) was determined in HepG2 cells with overexpression of Myc-tagged FAM13A. V: Vector control; F: Fam13a.(C) Immunoblotting showing the knockdown efficiency. Combo shRNA: combination of FAM13A shRNA and AMPK shRNA.(D) Bioenergetics assays measured by Seahorse in HepG2 cells with stable knockdown of FAM13A and/or AMPK by shRNA. Arrows indicated sequential addition of oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and rotenone/antimycin.(E) The basal oxygen consumption rate (OCR), maximal mitochondrial respiration, ATP production, and non-mitochondrial respiration were shown. Data are presented as mean ± SD. ∗p \< 0.05, ∗∗p \< 0.01 by unpaired Student\'s t test.Figure 7Schematic Illustration of FAM13A Regulating lipid and Glucose Metabolism(A) Mechanism of FAM13A regulating Hepatic steatosis and insulin resistance through AMPK. TG: triglycerides. HFD: high-fat diet.(B) Metabolic phenotypes observed in human subjects with opposing genotypes for SNP rs2276936 and *Fam13a*^*−/−*^ mice ([@bib11]).

Discussion {#sec3}
==========

Our current studies provided *in vivo* and *in vitro* evidence supporting important roles of FAM13A, a gene consistently associated with multiple metabolic phenotypes in GWAS, in regulating hepatic glucose and lipid metabolism. By reporter and CRISPR/Cas-9 assays, we pinpointed rs2276936 as the possible functional variant regulating hepatic FAM13A expression. Furthermore, we demonstrated that *Fam13a*^*−/−*^ mice are protected from HFD-induced fatty liver and lipid toxicity with improved hepatic insulin sensitivity. Increased AMPK activation associated with increased mitochondrial respiration was detected in hepatocytes from *Fam13a*^*−/−*^ mice, which likely contributes to ameliorated HFD-induced fatty liver in *Fam13a*^*−/−*^ mice. Importantly, most of the directional effects of risk allele rs2276936C were recapitulated in knockout mouse model, such as fat mass, insulin sensitivity, and total cholesterol levels ([Figure 7](#fig7){ref-type="fig"}B). Admittedly, some of human GWAS traits were not confirmed with genotypic difference in mouse models such as HDL levels, further highlighting the complexity of using mouse model to recapitulate human GWAS findings ([@bib25]).

From GWAS to Function {#sec3.1}
---------------------

Identification of functional variants in the GWAS locus is the crucial and necessary first step to translate genetic discoveries to disease understanding and ultimately, therapy. The FAM13A locus has been associated with BMI-adjusted fasting insulin level ([@bib17]), HDL level ([@bib29]), and waist-to-hip ratio ([@bib24]) in GWAS in multiple replicated studies. However, functional variants in this region and function of FAM13A gene in regulating metabolism *in vivo* remain incompletely understood yet. Here, we identified rs2276936 with allelic enhancer activities is located in the first intron of FAM13A, about ∼18kb away from its transcription start site. Interestingly, this SNP is also located nearby multiple enhancer marks including H3K4Me1, H3K27Ac, and H3K9Ac as well as DNase hypersensitive sites in liver, suggesting regulatory function of rs2276936. We primarily focused on roles of rs2276936 in liver here, given the importance of liver in regulating HDL, lipid, and glucose metabolism. Further investigations are warranted to determine roles of rs2276936 in adipose tissue and other metabolic active tissues. It is not surprising that pleiotropic functional variants may have effects on multiple tissues. For example, the significant BMI GWAS SNPs in the fat mass and obesity-associated (FTO) locus may regulate Iroquois homeobox 3 (Irx3) and Iroquois homeobox 5 (Irx5), the major causal genes ([@bib26]), in both brain ([@bib26]) and adipose tissues ([@bib3]). Functional variants regulating lipid GWAS gene sortilin 1 (Sort1) demonstrated greater allelic effects in the liver sample ([@bib20]) despite abundant expression of Sort1 in adipose tissues. These examples highlight the challenges and complexity of functional variants identification in GWAS loci in effect cell types.

It is noteworthy that rs2276936C, tightly correlated with previous top GWAS SNP rs9991328T ([Figure 1](#fig1){ref-type="fig"}A), is associated with reduced fat mass in human subjects ([Table S2](#mmc1){ref-type="supplementary-material"}) and reduced enhancer activity for Fam13A ([Figure 1](#fig1){ref-type="fig"}B), which is consistent with reduced body and fat weight in *Fam13a*^*−/−*^ *mice* ([Figures 2](#fig2){ref-type="fig"}A and 2C) in mouse models as we summarized in [Figure 7](#fig7){ref-type="fig"}.

Insulin Sensitivity in *Fam13a*^*−/−*^ Mice {#sec3.2}
-------------------------------------------

Through ITT measurements, we observed increased insulin sensitivity in *Fam13a*^*−/−*^ mice than *Fam13a*^*+/+*^ mice fed with HFD. However, no glucose tolerance difference was detected by GTT assay. This may result from compensatory reduction of insulin levels in *Fam13a*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}C).

Hepatic glucose production is also crucial for maintaining glucose homeostasis that is mainly controlled by gluconeogenesis through insulin and glucagon pathways. Reduced hepatic glucose production may result from increased insulin sensitivity in *Fam13a*^*−/−*^ hepatocytes through inhibition on the gluconeogenesis by insulin. Given that increased insulin sensitivity upon Fam13a deficiency was detected in primary hepatocytes isolated from normal chow- and HFD-fed mice, FAM13A likely intrinsically inhibits hepatic insulin sensitivity.

In contrast, the regulation of FAM13A on insulin sensitivity in adipose tissues seems more complex depending on the depots of white adipose tissue, which may explain previously inconsistent results ranging from reduced ([@bib28]) to similar ([@bib27]) insulin sensitivity in adipose tissues from *Fam13a*^*−/−*^ mice fed with HFD. We found variable changes of IRS-1 in different types of adipose tissues from *Fam13a*^*−/−*^ mice with a trend toward decreased levels of IRS-1 in epididymal fat ([Figure S4](#mmc1){ref-type="supplementary-material"}A), similar as previously reported ([@bib28]), whereas slightly increased IRS-1 levels in inguinal fat ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

Other reasons for some of the discrepancies between two previous studies and ours may include differences in the composition of diet, HFD treatment age and duration, genetic backgrounds of *Fam13a*^*−/−*^ mice, and technical details, which may complicate results interpretation. For example, an HFD containing 35% fat, 25.3% carbohydrates, and 23% protein was used previously to feed six-week-old *Fam13a*^*−/−*^ mice (C57BL/6N background) for 14 weeks compared with wild-type C57BL/6N mice in the studies ([@bib28]). Herein, four- to five-month-old *Fam13a*^*−/−*^ mice after three generations of backcrossing toward C57BL/6J background and *Fam13a*^*+/+*^ littermates were fed with HFD containing 36% fat, 35.7% carbohydrates, and 20.5% protein for four months. Furthermore, previous ITT assay was performed in mice without fasting ([@bib28]), in contrast to our ITT assay with mice after 6 h of fasting. Therefore, experimental condition is critical to interpret metabolic phenotypes in mice, and more stringently controlled studies are required to elucidate how FAM13A modulates insulin sensitivity in the adipose tissue.

Ameliorated Fatty Liver and Increased AMPK Activation in the *Fam13a*^*−/−*^ Mice {#sec3.3}
---------------------------------------------------------------------------------

Insulin sensitivity, body weight gain, and fatty liver can influence each other. Reduced body weight can possibly improve fatty liver and insulin resistance, whereas HFD-induced hepatic insulin resistance may lead to fatty liver due to failed inhibition on gluconeogenesis combined with selectively enhanced lipogenesis in liver by insulin ([@bib22]). In the present study, given reduced gluconeogenesis was found in isolated primary hepatocytes from *Fam13a*^*−/−*^ mice, it is likely ameliorated fatty liver resulted from improved hepatic insulin sensitivity. Furthermore, in HFD-fed *Fam13a*^*−/−*^ mice, despite increased hepatic insulin sensitivity, improved fatty liver was found without significantly increased lipogenesis by insulin pathway, possibly due to hepatic activation of AMPK. Admittedly, future studies using liver-specific *Fam13a*^*−/−*^ mice will be helpful to conclusively exclude the possibility of improved fatty liver resulting from less body weight gain in *Fam13a*^*−/−*^ mice.

AMPK is activated by reduced ATP/AMP ratio due to prolonged energy deprivation, thus facilitating utilization of various sources of nutrients to generate ATP. Consequently, upon AMPK activation, ATP-consuming pathways, including cholesterol and fatty acid synthesis, are repressed and ATP-generating pathways, including fatty acid oxidation and lipolysis, are activated ([@bib30]) through regulatory enzymes or regulatory proteins involved in anabolic pathways ([@bib9]). For example, AMPK represses cholesterol synthesis by inhibiting sterol regulatory element-binding factor 2 (Srebf2) and hydroxymethylglutaryl-CoA (HMG-CoA) reductase ([@bib16]). Therefore, activation of AMPK in primary hepatocytes isolated from *Fam13a*^*−/−*^ mice may explain reduced cholesterol levels in serum from *Fam13a*^*−/−*^ mice fed with normal chow ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Furthermore, increased mitochondrial respiration in primary *Fam13a*^*−/−*^ hepatocytes is also consistent with enhanced expression of Ppargc1α, a key gene essential for mitochondrial synthesis and regulated by AMPK ([@bib9]).

AMPK was recently suggested as a therapeutic target for the treatment of obesity, fatty liver disease ([@bib6]), and type 2 diabetes ([@bib5]) due to its importance as a master regulator in maintaining glucose and lipid homeostasis. For example, genetic or pharmacological activation of AMPK in murine livers decreased lipogenesis, ameliorated high-fructose-induced hepatic triglyceride accumulation and thus improved hepatic steatosis ([@bib30]), similar as we observed in HFD-fed *Fam13a*^*−/−*^ mice. Notably, hepatic activation of AMPK by overexpression of trancated AMPKα1 induced by doxycycline treatment improved HFD-induced weight gain and white fat depot accumulation, even after obesity and fatty liver disease have been established ([@bib6]). In addition, such hepatic activation of AMPK usually does not reduce levels of blood glucose ([@bib4], [@bib30]), as we observed as well ([Figure S2](#mmc1){ref-type="supplementary-material"}I). Admittedly, hepatic role of AMPK activation in regulating body weight gain is far more complex. Despite knockin of activating mutations in the AMPKγ2 subunit reduced fat mass and liver steatosis upon diet-induced obesity ([@bib32]), liver-specific constitutive activation of AMPK protected mice against only high-fructose diet-induced liver steatosis ([@bib30]), in contrast to HFD treatment.

It is likely that hepatic activation of AMPK pathway may not explain all the metabolic phenotypes that we observed in *Fam13a*^*−/−*^ mice, and future studies using hepatocyte-specific and/or adipocyte-specific Fam13a knockout mice may help explain the pleotrophic regulation of FAM13A on glucose and lipid metabolism. Nonetheless, our study provides several lines of evidence to reveal that a common DNA variant rs2276936 associated with four metabolic traits regulates hepatic expression of FAM13A. *Fam13a*^*−/−*^ mice are protected from HFD-induced weight gain, hepatic lipid accumulation, and insulin resistance, possibly by increasing the AMPK activity. More importantly, in human subjects, FAM13A locus is associated with lipid metaoblism and insulin sensitivity and increased expression of FAM13A was found in liver cirrhosis tissues compared with normal liver samples ([@bib35]). Given protective effects of Fam13a deficiency in diet-induced fatty liver, our results suggest FAM13A as a possible interventional target for the treatment of obesity and fatty liver disease.

Limitations of the Study {#sec3.4}
------------------------

We demonstrated that deficiency of FAM13A protected mice from HFD-induced obesity and fatty liver using a global Fam13a knockout mouse line. To conclusively determine whether FAM13A deficiency in liver or fat contributes to amolriated body weight gain and lipid accumulation in liver after HFD treatment, future studies with hepatocyte-specific *Fam13a*^*−/−*^ mice and adipose-specific *Fam13a*^*−/−*^ mice are warranted. Secondly, despite phosphorylation of AMPK at Thr172 has been widely used to indicate AMPK activity, future more compreheisve evalautation on AMPK acitivty measured by AMPK activity kits including tissue-speicific regulation of AMPK by FAM13A would strengthen our findings. Lastly, future work will also include testing the silencing of Fam13a as a possible treatment strategy in diet-induced obesity and fatty liver mouse models.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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